Blog entry by Meguid El Nahas
SHARP Study GRoup.
The SHARP study group showed in their original publication that lipids lowering with a combination of simvastatin and ezetimibe had little effect on overall or cardiovascular mortality in CKD.
They also showed that lipid lowering had no effect on CKD progression.
Now, it seems as if the SHARP study group has embraked on republisihng these findings individually.
In this month JASN (August 2014), a paper entitled:
Effects of lowering LDL cholesterol on progression of kidney disease...NO EFFECT.
But this is a duplicated result to that published in the original SHARP report!?
I am suprised that top quality journals dont preclude publication duplications.
I expect to see over th enext few months more SHARP Publications:
Lipids lowering on CAD: NIL....
Lipids lowering on Overall Strokes incidence: NIL....
Lipids lowering on Non-Cardiovascular Mortality....NIL
Lipids Lowering on Cardiovascular Mortality...NIL
MANY PAPERS IN PROSPCET FOR THE SHARP COLLABORATIVE GROUP...
VERY LITTLE NEW INFORMATION IN STORE FOR THE NEPHROLOGISTS...!